今年の「Drugs to Watch 2025」に含まれるリストは、160 人以上のクラリベイトのアナリストが、数百の疾患、医薬品および市場をカバーする専門知識を活用し、研究開発から商業化のライフサイクルまでの広い範囲を網羅する11の統合データセットを用いて特定したものです。
| Drug Name | Company | Therapy Area | Year |
| Ocrelizumab (Ocrevus) | Roche | Neurology/psychiatric | 2017 |
| Ribociclib (LEE-011; Kisqali) | Novartis International AG | Oncology | 2017 |
| Semaglutide (Ozempic) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2017 |
| Gardasil 9 vaccine | Merck & Co. | Infectious disease | 2015 |
| Insulin glargine (Toujeo) | Sanofi SA | Endocrinology/metabolic disease | 2015 |
| Lumacaftor plus ivacaftor (Orkambi) | Vertex Pharmaceuticals Inc. | Respiratory disease | 2015 |
| Nivolumab (Opdivo) | Bristol-Myers Squibb Co. | Oncology | 2015 |
| Palbociclib (Ibrance) | Pfizer Inc. | Oncology | 2015 |
| Sacubitril plus valsartan (LCZ-696) | Novartis International AG | Cardiovascular disease | 2015 |
| Secukinumab (Cosentyx) | Novartis International AG | Excessive immune response/autoimmunity | 2015 |
| Veruprevir, ritonavir, ombitasvir and dasabuvir (Viekira Pak) | AbbVie Inc. | Respiratory disease | 2015 |
| Idelalisib (Zydelig) | Gilead Sciences Inc. | Oncology | 2014 |
| Sofosbuvir (Sovaldi) | Gilead Sciences Inc. | Infectious disease | 2014 |
| Filgotinib (GLPG-0634) | Galapagos NV, Gilead Sciences Inc. | Excessive immune response/autoimmunity | 2020 |
| Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si; Leqvio) | The Medicines Co. | Cardiovascular disease | 2020 |
| Lisocabtagene maraleucel (JCAR-017; Liso-cel) | Celgene Corporation | Oncology | 2020 |
| Ofatumumab (OMB-157; Kesimpta) | Novartis International AG | Neurology/psychiatric | 2020 |
| Ozanimod (RPC-1063; Zeposia) | Celgene Corporation | Neurology/psychiatric | 2020 |
| Rimegepant (BHV-3000; Nurtec) | Biohaven Pharmaceutical Holding Co. Ltd. | Neurology/psychiatric | 2020 |
| Sacituzumab govitecan (IMMU-132) | Immunomedics Inc., Medicine Inc. | Oncology | 2020 |
| Semaglutide (Rybelsus) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2020 |
| Apalutamide (Erleada) | Johnson & Johnson | Oncology | 2018 |
| Buprenorphine (Sublocade) | Indivior plc | Addiction | 2018 |
| Cannabidiol (Epidiolex) | GW Pharmaceuticals plc | Neurology/psychiatric | 2018 |
| Elagolix (Orilissa) | AbbVie Inc. | Reproductive health | 2018 |
| Emicizumab (Hemlibra) | Chugai, Roche | Hematology | 2018 |
| Erenumab (Aimovig) | Amgen, Novartis International AG | Neurology/psychiatric | 2018 |
| Ertugliflozin (Steglatro) | Merck & Co., Pfizer Inc. | Endocrinology/metabolic disease | 2018 |
| Lanadelumab (Takhzyro) | Shire | Genetic disorder | 2018 |
| Patisiran (Onpattro) | Alnylam Pharmaceuticals Inc., Sanofi Genzyme | Genetic disorder | 2018 |
| Shingrix vaccine | GlaxoSmithKline plc | Infectious disease | 2018 |
| Emtricitabine plus tenofovir alafenamide (Descovy) | Gilead Sciences Inc., Japan Tobacco | Infectious disease | 2016 |
| Grazoprevir plus elbasvir (MK-5172A) | Merck & Co. | Infectious disease | 2016 |
| Obeticholic acid (Ocaliva) | Intercept Pharmaceuticals, Sumitomo Dainippon Pharma | Hepatology | 2016 |
| Pimavanserin (Nuplazid) | ACADIA Pharmaceuticals | Neurology/psychiatric | 2016 |
| Tenofovir alafenamide plus emtricitabine plus rilpivirine (Odefsey) | Gilead Sciences Inc., Janssen R&D | Infectious disease | 2016 |
| Selexipag (Uptravi) | Actelion, Nippon Shinyaku Co. | Cardiovascular disease | 2016 |
| Venetoclax (Venclexta; Venclyxto) | AbbVie Inc. | Oncology | 2016 |
| Alirocumab (Praluent) | Regeneron Pharmaceuticals Inc., Sanofi SA | Cardiovascular disease | 2015 |
| Brexpiprazole (Rexulti) | Lundbeck, Otsuka Pharmaceutical | Neurology/psychiatric | 2015 |
| Evolocumab (Repatha) | Amgen, Astellas Pharma Inc. | Cardiovascular disease | 2015 |
| Vilanterol plus umeclidinium (Anoro Ellipta) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2014 |
| Apremilast (Otezla) | Celgene Corporation | Excessive immune response/autoimmunity | 2013 |
| Fluticasone furoate plus vilanterol trifenatate (Relovair) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2013 |
| Icosapent ethyl ester (Vascepa) | Amarin Corporation plc | Cardiovascular disease | 2013 |
| Pomalidomide (Pomalyst) | Celgene Corporation | Oncology | 2013 |
| Trastuzumab emtansine (T-DM1) | Roche | Oncology | 2013 |
| Umeclidinium plus vilanterol (Zephyr) | GlaxoSmithKline plc, Theravance Biopharma Inc. | Respiratory disease | 2013 |
| AWIQLI | Novo Nordisk A/S | Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM) | 2025 |
| CagriSema | Novo Nordisk A/S | Type 2 diabetes mellitus (T2DM) | 2025 |